Trial Profile

A phase 3 trial of BH-200

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BH-200 (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

15 Jun 2026 According to a HMNC Brain Health media release, the company announced the successful $50 million first closing of its Series B financing which will support the advancement of Phase 3-readiness activities.
30 Sep 2025 According to a HMNC Brain Health, the company plans to initiate regulatory discussions for Phase 3 development of BH-200.
30 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com